48MO Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)
Year: 2021
Type: article
Source: Journal of Thoracic Oncology
Institutions: Spanish National Cancer Research Centre, Hospital Universitario 12 De Octubre, Emory University, Sarah Cannon, Tennessee Oncology, Washington University in St. Louis, National Cancer Center Hospital East, Memorial Sloan Kettering Cancer Center, Fox Chase Cancer Center, Chris O’Brien Lifehouse, The Netherlands Cancer Institute, Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, The Christie Hospital, The Christie NHS Foundation Trust, University Hospitals Seidman Cancer Center, Case Western Reserve University, Amgen (United States), Université Paris-Saclay, Institut Gustave Roussy
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Celgene, Emory University, RefleXion Medical, United Therapeutics Corporation, Array BioPharma, Regeneron Pharmaceuticals, Aeglea BioTherapeutics, Clovis Oncology, Jounce Therapeutics, Mersana Therapeutics, Mirati Therapeutics, BeiGene, Incyte, Calithera Biosciences, Association of Community Cancer Centers, Tarveda Therapeutics, Syndax Pharmaceuticals, Ribon Therapeutics, Advanced Accelerator Applications, G1 Therapeutics, Eisai, Astellas Pharma, Servier, PharmaMar, Ipsen, Genentech, EMD Serono, School of Medicine, Emory University, Daiichi Sankyo Europe
OpenAlex ID: W3151400403